Aktie 300204 STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Aktien

300204

CNE100001237

300204

Schlusskurs Shenzhen S.E.
Andere Börsenplätze
 00:00:00 10.05.2024 		% 5 Tage % 1. Jan.
6,77 CNY -4,38 % Intraday Chart für Staidson (Beijing) BioPharmaceuticals Co., Ltd. +1,35 % -33,37 %
24.04. Staidson (Beijing) BioPharmaceuticals Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
25.03. Staidson (Beijing) BioPharmaceuticals Co., Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Staidson BioPharmaceuticals Co., Ltd.(XSEC:300204) added to S&P Global BMI Index
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Staidson BioPharmaceuticals Co., Ltd. amended terms of the transaction
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Staidson Pharma Unit Gets FDA's Emergency Use Authorization for COVID-19 Drug; Shares Soar 18%
Review Into Staidson Biopharma Unit's Anti-COVID-19 Drug Shows Safety, Tolerability in Patients; Shares Jump 5%
Staidson's Respiratory Drug Shows Safety in Trial
Chinese Shares Finish Lower; Staidson Falls 8% After Signing R&D Deal With Germany’s InflaRx
Staidson Forms R&D Deal With Germany’s InflaRx
Staidson BioPharmaceuticals Co., Ltd. announced that it expects to receive CNY 580 million in funding
Inflarx Gmbh and Staidson Biopharmaceuticals Co., Ltd Enters into Third Addendum to the Co-Development Agreement
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson BioPharmaceuticals Co., Ltd.
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 300204 Aktie
  4. Nachrichten Staidson (Beijing) BioPharmaceuticals Co., Ltd.
  5. Andere Sprachen